Enterovirus Assay (GXEA) (Cepheid, Sunnyvale, CA) (10) . GXEA is at present the only FDA-23 approved assay for qualitative detection of enterovirus RNA in CSF. It combines automated 24 nucleic acid sample preparation, amplification and real-time detection of enteroviral RNA in a 25 disposable, macro/microfluidic cartridge using the GeneXpert Dx system instrument. To date, 26 only one evaluation of GXEA has been published in peer reviewed journals. A multicenter 27 beta trial on 102 CSF samples obtained from patients with suspected meningitis (34 28 was tested for the presence of enterovirus RNA using GXEA and in-house real-time PCR on 63 the same day. Since the in-house real-time PCR assay had been implemented in daily 64 routine only 7 months before starting of GXEA evaluation and due to lack of an internal 65 control in the in-house real-time PCR, all CSF samples were additionally tested once weekly 66 using Enterovirus Consensus Kit (Argene SA, Varilhes, France), following the manufacturer's 67 instructions, as described previously (6). Briefly, 10 µl of RNA previously extracted for the in-68 house real-time PCR and stored for a maximum of one week at -70°C was amplified using 69 one-step reverse-transcription PCR and primers targeting a 425 bp region of the 5'-non 70 coding region followed by detection of PCR products in a microtiter plate using a biotinylated 71 probe. The in house real-time PCR and Argene assay were performed by two technicians 72 with substantial experience in molecular diagnostics while GXEA testing was performed by 8 73 operators, mainly without any experience in molecular diagnostics. Table 2 . All samples with discordant results were retested using all three assays. Of 5 initially 85
A C C E P T E D
Argene negative samples, 3 samples became positive on repeat while 2 samples remained 86
Argene enterovirus negative in repeated testing ( Table 1 ). The latter two samples which 87 tested repeatedly negative using the Argene assay but repeatedly GXEA and in-house RT-88 PCR positive were finally considered to be false negative results for the Argene assay. In 89 both patients these results were supported by clinical diagnoses of enteroviral meningitis and 90 their CSF samples tested negative for HSV DNA, CMV DNA, VZV DNA, EBV DNA, HHV-6 91 DNA; these samples were also IgM and RNA negative for tick-borne encephalitis virus. Of 8 92 initially GXEA negative samples, 7 tested enterovirus positive while one sample remained 93 GXEA negative upon repeat ( Table 1 ). The latter sample, which tested repeatedly GXEA 94 negative but repeatedly Argene assay and real-time PCR positive was finally considered to 95 be a GXEA false negative. This result was supported by clinical diagnosis of enteroviral 96 meningitis, and CSF and blood samples tested negative for all previously listed viruses. The 97 most surprising finding in this evaluation were 7 initially GXEA negative samples which all 98 became highly positive upon repeat testing. Although these 7 samples were initially reported 99 as enterovirus negative by the GeneXpert Dx instrument, we noticed after the first such 100 discrepant result (due to non-blinded nature of our comparative evaluation) that the end-point 101 fluorescence in these samples showed some evidence of enteroviral amplification signal 102 ranging from 3 to 15. In contrast, results from concordant enterovirus negative specimens 
